Recursion Pharmaceuticals Details AI-Driven Drug Pipeline, Sanofi/Roche Milestones, Runway to 2028 [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Yahoo! Finance
Recursion Pharmaceuticals (NASDAQ:RXRX) Chief Financial Officer Ben Taylor outlined the company's integrated approach to AI-enabled drug discovery and development, recent portfolio decisions, partnership economics, and cash runway during a fireside chat hosted by KeyBank healthcare tech equity analyst Scott Schoenhaus. Combining AI-driven biology, chemistry, and clinical execution Taylor, who joined Recursion through the merger with Exscientia about 18 months ago, described how the combined company aims to address multiple points of failure in drug development. He said Exscientia brought strengths in using AI for chemistry, including multi-parameter optimization that considers not only potency and selectivity, but also absorption, metabolism, and toxicity-related properties. ? Forget Chipmakers: Walmart and Target Are the Real AI Plays These Are the Only 6 Stock Stocks in NVIDIA's 13F Portfolio On the legacy Recursion side, Taylor emphasized the company's focus on generatin
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Jim Cramer on Recursion Pharmaceuticals: “It's a Let Down, Big Let Down” [Yahoo! Finance]Yahoo! Finance
- Is Recursion Pharmaceuticals (RXRX) Pricing Reflect Recent 1-Year Share Slump Accurately [Yahoo! Finance]Yahoo! Finance
- Recursion's First AI Clinical Proof Links Pipeline Progress With Valuation Gap [Yahoo! Finance]Yahoo! Finance
- What Makes Recursion Pharmaceuticals (RXRX) So Attractive [Yahoo! Finance]Yahoo! Finance
- Can This AI Stock Bounce Back in 2026? [Yahoo! Finance]Yahoo! Finance
RXRX
Earnings
- 2/25/26 - Beat
RXRX
Sec Filings
- 3/23/26 - Form 144
- 3/18/26 - Form 4
- 3/17/26 - Form 144
- RXRX's page on the SEC website